Menu
← Oncology Approval Tracker
FDA DECISION ·
Mylotarg
gemtuzumab ozogamicin · Wyeth Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Expanded the newly diagnosed CD33-positive acute myeloid leukemia indication to children aged one month and older.
LAMPGEN ANALYSIS
Why it matters
Extended a CD33-directed antibody-drug conjugate to very young patients with newly diagnosed disease.
What research teams should watch
Document CD33 status and age-specific dosing and monitor liver complications around transplant.
PRIMARY RECORDS